The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Performance status assessment in cancer patients. An inter-observer variability study
Open accessAbstract
The ECOG Scale of Performance Status (PS) is widely used to quantify the functional status of cancer patients, and is an important factor determining prognosis in a number of malignant conditions. The PS describes the status of symptoms and functions with respect to ambulatory status and need for care. PS 0 means normal activity, PS 1 means some symptoms, but still near fully ambulatory, PS 2 means less than 50%, and PS 3 means more than 50% of daytime in bed, while PS 4 means completely bedridden. An inter-observer variability study of PS assessment has been carried out to evaluate the non-chance agreement among three oncologists rating 100 consecutive cancer patients. Total unanimity was observed in 40 cases, unanimity between two observers in 53 cases, and total disagreement in seven cases. Kappa statistics reveal the ability of the observers compared to change alone and were used to evaluate non-chance agreement. Overall Kappa was 0.44, (95% confidence limits 0.38-0.51). The Kappa for PS 0 was 0.55 (0.44-0.67), while those for PS 1, 2, 3 and four were 0.48 (0.37-0.60), 0.31 (0.19-0.42), 0.43 (0.32-0.55), and 0.33 (0.33-0.45), respectively. If one observer allocated patients to PS 0-2, then another randomly selected observed placed the patients in the same category with a probability of 0.92. For patients with PS 3-4 the probability that the same category would be chosen was 0.82. Overall, the non-chance agreement between observers was only moderate, when all ECOG Performance Status groups were considered. However, agreement with regard to allocation of patients to PS 0-2 versus 3-4 was high. This is of interest because this cut-off is often used in clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398
Karnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517
Mor, V., Laliberte, L., Morris, J. N., & Wiemann, M. (1984) · Cancer · doi:10.1002/1097-0142(19840501)53:9<2002::aid-cncr2820530933>3.0.co;2-w · Cited by 1,067
Schipper, H., Clinch, J., McMurray, A., & Levitt, M. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.5.472 · Cited by 1,052
Who should measure quality of life, the doctor or the patient?
Slevin, M., Plant, H., Lynch, D., Drinkwater, J., & Gregory, W. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.20 · Cited by 904
Evaluation of patients with advanced cancer using the karnofsky performance status
Yates, J. W., Chalmer, B., & McKegney, F. P. (1980) · Cancer · doi:10.1002/1097-0142(19800415)45:8<2220::aid-cncr2820450835>3.0.co;2-q · Cited by 898
A Re-analysis of the Reliability of Psychiatric Diagnosis
Spitzer, R. L., & Fleiss, J. L. (1974) · British Journal of Psychiatry · doi:10.1192/bjp.125.4.341 · Cited by 612
The Reliability of Clinical Methods, Data and Judgments: (Second of Two Parts)
Koran, L. M. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510022931405 · Cited by 400
Performance status assessment in cancer patients
Conill, C., Verger, E., & Salamero, M. (1990) · Cancer · doi:10.1002/1097-0142(19900415)65:8<1864::aid-cncr2820650832>3.0.co;2-u · Cited by 361
Scientific problems in clinical scales, as demonstrated in the karnofsky index of performance status
Hutchinson, T. A., Boyd, N. F., & Feinstein, A. R. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90096-1 · Cited by 238
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708
Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Llovet, J. M., Vilana, R., Brú, C., Bianchi, L., Salmeron, J. M., Boix, L., Ganau, S., Sala, M., Pagès, M., Ayuso, C., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.24233 · Cited by 759
Buccheri, G., Ferrigno, D., & Tamburini, M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00664-8 · Cited by 629
Sangiovanni, A., Prati, G. M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., Del Ninno, E., Morabito, A., & Colombo, M. (2006) · Hepatology · doi:10.1002/hep.21176 · Cited by 628
Sangiovanni, A., Del Ninno, E., Fasani, P., De Fazio, C., Ronchi, G., Romeo, R., Morabito, A., de Franchis, R., & Colombo, M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.049 · Cited by 600
Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. D. C., Vilana, R., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270617 · Cited by 533
Burrel, M., Reig, M., Forner, A., Barrufet, M., Lope, C. R. D., Tremosini, S., Ayuso, C., Llovet, J. M., Real, M. I., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.008 · Cited by 485
Treatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Llovet, J. M., Bruix, J., Fuster, J., Castells, A., Garcia-Valdecasas, J. C., Grande, L., França, A., Brú, C., Navasa, M., Ayuso, M. D., et al. (1998) · Hepatology · doi:10.1002/hep.510270616 · Cited by 382
Azam, F., Latif, M. F., Farooq, A., Tirmazy, S. H., AlShahrani, S., Bashir, S., & Bukhari, N. (2019) · Case Reports in Oncology · doi:10.1159/000503095 · Cited by 374
Kluetz, P. G., Chingos, D. T., Basch, E. M., & Mitchell, S. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159514 · Cited by 361
Kluetz, P. G., Slagle, A., Papadopoulos, E. J., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., Chen, W.-H., Sridhara, R., Farrell, A. T., Keegan, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2035 · Cited by 334
Sala, M., Fuster, J., Llovet, J. M., Navasa, M., Solé, M., Varela, M., Pons, F., Rimola, A., García-Valdecasas, J. C., Brú, C., et al. (2004) · Liver Transplantation · doi:10.1002/lt.20202 · Cited by 297
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271
A framework for evaluating clinical artificial intelligence systems without ground-truth annotations
Kiyasseh, D., Cohen, A., Jiang, C., & Altieri, N. (2024) · Nature Communications · doi:10.1038/s41467-024-46000-9 · Cited by 26
“Additionally, in the context of real world evidence, ECOG PS can be used to identify study cohorts of interest (typically those with ECOG PS 2 34 ).”
Chinh, K., Secinti, E., Johns, S., Hirsh, A., Miller, K., Schneider, B., Storniolo, A. M., Mina, L., Newton, E., Champion, V., et al. (2020) · Oncology Nursing Forum · doi:10.1188/20.onf.739-752 · Cited by 17
“Patients were ineligible if they had a self-reported Eastern Cooperative Oncology Group (ECOG) (Sørensen et al., 1993) Performance Status score of greater than 2 (able to do little activity), showed severe cognitive impairment (three or more errors on a six-item cognitive function screener)…”
BackgroundMethodInfluential
Metadata
- Authors
- Sørensen, J., Klee, M., Palshof, T., & Hansen, H.
- Venue
- British Journal of Cancer
- Published
- 1993-04
- Volume
- 67
- Issue
- 4
- Pages
- 773-775
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2058786880
- Cited by
- 483
- References
- 12
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.